LSK Investment Selected as Manager for K-Bio and Vaccine Fund No. 3

Early Investment Launch Upon Raising 70 Billion Won

The Ministry of Health and Welfare announced on the 13th that it has selected 'LSK Investment' as the lead manager for the K-Bio·Vaccine Fund No. 3, which is worth 100 billion KRW.

The K-Bio·Vaccine Fund was established with the purpose of investing in pharmaceutical and bio companies to develop innovative new drugs and secure vaccine sovereignty. It focuses on investing in innovative new drug clinical phases 2-3, innovative pharmaceutical technologies, the global expansion of domestic companies, M&A, and other innovative pharmaceutical and biohealth companies.

Previously, the K-Bio·Vaccine Fund No. 1 was raised by Yuanta Investment with 150 billion KRW, and Fund No. 2 was raised by Premier Partners with 114.6 billion KRW.

The target fundraising amount for this fund is 100 billion KRW, with a minimum (priority) fundraising amount of 70 billion KRW. Considering the contraction of the investment market, the government and policy banks have invested the entire amount of 40 billion KRW regardless of the fundraising scale, and early investment can begin once the minimum (priority) fundraising amount is reached.

Jung Eun-young, Director of the Health Industry Policy Bureau at the Ministry of Health and Welfare, said, "In a situation where biohealth investment sentiment is weakened, a management company with excellent capabilities has been selected as the lead manager for the K-Bio·Vaccine Fund No. 3. We expect that through rapid fund formation, investment will commence and serve as a catalyst for revitalizing biohealth investment."

This content was produced with the assistance of AI translation services.